
José Palacios

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5616680/publications.pdf Version: 2024-02-01



Ιοςà Ο Ρλιλείος

#	Article	IF	CITATIONS
1	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. Cancer Research, 2008, 68, 989-997.	0.9	934
2	Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. American Journal of Pathology, 1993, 142, 987-93.	3.8	288
3	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. Cancer Research, 2006, 66, 9543-9556.	0.9	285
4	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
5	Microâ€RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. Journal of Pathology, 2011, 223, 72-80.	4.5	194
6	Epigenetic and genetic alterations of <i>APC</i> and <i>CDH1</i> genes in lobular breast cancer: Relationships with abnormal Eâ€cadherin and catenin expression and microsatellite instability. International Journal of Cancer, 2003, 106, 208-215.	5.1	186
7	Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene, 2004, 23, 3272-3283.	5.9	185
8	The morphological and molecular features of the epithelial-to-mesenchymal transition. Nature Protocols, 2009, 4, 1591-1613.	12.0	185
9	Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. Journal of Pathology, 2005, 207, 1-13.	4.5	172
10	Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. Journal of Pathology, 2008, 215, 231-244.	4.5	153
11	β-Catenin Expression Pattern, β-Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas. Diagnostic Molecular Pathology, 2001, 10, 116-122.	2.1	138
12	Genomic and mutational profiling of ductal carcinomas <i>in situ</i> and matched adjacent invasive breast cancers reveals intraâ€ŧumour genetic heterogeneity and clonal selection. Journal of Pathology, 2012, 227, 42-52.	4.5	138
13	Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry. American Journal of Surgical Pathology, 2013, 37, e1-e11.	3.7	137
14	Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Annals of Oncology, 2012, 23, 625-631.	1.2	106
15	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer, 2001, 92, 2829-2836.	4.1	103
16	The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma. Modern Pathology, 2001, 14, 650-654.	5.5	85
17	MicroRNA-200 Family Modulation in Distinct Breast Cancer Phenotypes. PLoS ONE, 2012, 7, e47709.	2.5	85
18	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. Oncotarget, 2016, 7, 56295-56308.	1.8	83

2

JOSé PALACIOS

#	Article	IF	CITATIONS
19	Frequent E-cadherin Gene Inactivation by Loss of Heterozygosity in Pleomorphic Lobular Carcinoma of the Breast. Modern Pathology, 2003, 16, 674-678.	5.5	81
20	Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Modern Pathology, 2016, 29, 1390-1398.	5.5	80
21	Pathogenetic Pathways in Ovarian Endometrioid Adenocarcinoma. American Journal of Surgical Pathology, 2009, 33, 1157-1163.	3.7	72
22	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Human Pathology, 2006, 37, 1042-1049.	2.0	69
23	ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Modern Pathology, 2013, 26, 1514-1524.	5.5	68
24	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. Journal of Pathology, 2014, 232, 319-329.	4.5	66
25	Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocrine-Related Cancer, 2015, 22, 443-454.	3.1	66
26	E-cadherin expression in basal cell carcinoma. British Journal of Cancer, 1994, 69, 157-162.	6.4	65
27	Functional characterization of E- and P-cadherin in invasive breast cancer cells. BMC Cancer, 2009, 9, 74.	2.6	61
28	Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. Cancers, 2019, 11, 964.	3.7	54
29	VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. Endocrine-Related Cancer, 2014, 21, 587-599.	3.1	53
30	Zeb1 and <scp>S</scp> nail1 engage mi <scp>R</scp> â€200f transcriptional and epigenetic regulation during <scp>EMT</scp> . International Journal of Cancer, 2015, 136, E62-73.	5.1	52
31	Mismatch Repair Deficiency in Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 649-656.	3.7	44
32	β-Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 599-604.	2.8	41
33	Apical mitochondria-rich cells in the human epididymis: An ultrastructural, enzymohistochemical, and immunohistochemical study. The Anatomical Record, 1991, 231, 82-88.	1.8	33
34	High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features. Cancers, 2019, 11, 74.	3.7	33
35	Loss of the tumor suppressor spinophilin (PPP1R9B) increases the cancer stem cell population in breast tumors. Oncogene, 2016, 35, 2777-2788.	5.9	31
36	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. Human Pathology, 2013, 44, 244-254.	2.0	30

JOSé PALACIOS

#	Article	IF	CITATIONS
37	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. Cancers, 2020, 12, 1832.	3.7	30
38	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. Modern Pathology, 2015, 28, 1492-1503.	5.5	23
39	The Frequency and Prognostic Significance of the Histologic Type in Early-stage Ovarian Carcinoma. American Journal of Surgical Pathology, 2020, 44, 149-161.	3.7	21
40	Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. Journal of Clinical Pathology, 2021, , jclinpath-2020-207337.	2.0	18
41	RNA SARS-CoV-2 Persistence in the Lung of Severe COVID-19 Patients: A Case Series of Autopsies. Frontiers in Microbiology, 2022, 13, 824967.	3.5	18
42	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. European Journal of Cancer, Supplement, 2020, 15, 1-15.	2.2	15
43	Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients. Human Pathology, 2014, 45, 2437-2446.	2.0	13
44	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. International Journal of Molecular Sciences, 2021, 22, 7398.	4.1	13
45	Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin. 2020. 476. 195-207.	2.8	12
46	Pulmonary vascular proliferation in patients with severe COVID-19: an autopsy study. Thorax, 2021, 76, 1044-1046.	5.6	12
47	Neuropathological findings in fatal COVID-19 and their associated neurological clinical manifestations. Pathology, 2022, 54, 738-745.	0.6	12
48	Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature. Diagnostic Pathology, 2018, 13, 62.	2.0	11
49	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. Cancers, 2021, 13, 5416.	3.7	7
50	Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clinical and Translational Oncology, 2018, 20, 274-285.	2.4	5
51	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. Cancers, 2022, 14, 1151.	3.7	5
52	Modified SureSelectQXT Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples. Biological Procedures Online, 2018, 20, 19.	2.9	4
53	Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma. Cancers, 2021, 13, 233.	3.7	4
54	Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer. Diagnostic Pathology, 2020, 15, 84.	2.0	3

#	Article	IF	CITATIONS
55	Immuneâ€related gene expression signatures: a step forward in the stratification of patients with ovarian clear cell carcinoma â€. Journal of Pathology, 2021, , .	4.5	Ο